Objective:

To evaluate the efficacy and safety of Nivolumab-AVD compared to BV-AVD in treating advanced-stage classical Hodgkin lymphoma (cHL).

Key Findings:

• Nivolumab-AVD showed a one-year progression-free survival (PFS) rate of 94% compared to 86% for BV-AVD.
• Neutropenia was more common in the Nivo-AVD group (56%) compared to BV-AVD (34%).
• Nivolumab-AVD was better tolerated, with lower rates of peripheral sensory neuropathy (29% vs. 56%).
• Older patients (over 60) had a PFS rate of 93% with Nivo-AVD versus 64% with BV-AVD.

Interpretation:

Nivolumab-AVD demonstrates superior efficacy and a more favorable safety profile compared to BV-AVD in treating advanced-stage cHL, particularly in older patients.

Limitations:

• The study results are based on interim analyses and require confirmation from larger phase III trials.
• Long-term toxicity and quality of life outcomes need further investigation.

Conclusion:

Nivolumab-AVD represents a promising treatment option for advanced-stage classical Hodgkin lymphoma, with improved efficacy and tolerability compared to traditional therapies.